Breaking News

Akcea, Pfizer Enter Licensing Agreement for Antisense Therapy

AKCEA-ANGPTL3-LRx is in Phase II development for the treatment of certain cardiovascular and metabolic diseases

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, and Pfizer, have entered into an exclusive worldwide licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat certain cardiovascular and metabolic diseases. AKCEA-ANGPTL3-LRx is designed to reduce the production of angiopoietin-like 3 (ANGPTL3) protein in the liver, a key regulator of triglycerides, cholesterol, glucose and energy metabolism. AKCEA-ANGPTL3-LRx is currently being e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters